ScoreHaematology

WHO classification-based Prognostic Scoring System for MDS (WPSS)

Classifies myelodysplastic syndrome patients into five risk groups for survival and leukaemic progression.

Updated 30 October 2026

When to use it

MDS classified by WHO 2001/2008, at diagnosis or at any time during follow-up (dynamic model).

What it needs

  • WHO categoryOptions: RA, RARS or MDS with isolated del(5q) · RCMD (with or without ring sideroblasts) · RAEB-1 · RAEB-2
  • KaryotypeOptions: Good · Intermediate · Poor
  • Transfusion requirementOptions: None · Regular

The points for each answer and the automatic total are in the app.

How to interpret it

WPSS score
ResultInterpretation
≤ 0Very low risk
1Low risk
2Intermediate risk
3–4High risk
≥ 5Very high risk

Practical tip

Regular transfusion requirement: sustained red cell transfusions, roughly at least one every 8 weeks over several months.

2 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top